Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients: Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma. Cohort B: Patients with locally advanced resectable Myxoid Liposarcoma. Cohort C: Patients with retroperitoneal and resectable soft tissue sarcoma (liposarcoma and leiomyosarcoma). Cohort D (Phase II only): Patients with well differentiated liposarcoma and G2 dedifferentiated liposarcoma (with less than

Trial Details

NCT ID
NCT02275286
Phase
PHASE1 / PHASE2
Sponsor
Grupo Espanol de Investigacion en Sarcomas
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Trabectedin
  • Radiotherapy
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Lyon, France|45.74906,4.84789
  • Rozzano, Milan, Italy|45.38193,9.1559
  • Aviano, Italy|46.07056,12.59472
  • Bologna, Italy|44.49381,11.33875

Key Eligibility Criteria

  • The patient must sign voluntarily the informed consent form before any study test is conducted that is not part of routine patient care.
  • Aged equal or over 18.
  • Patients must have a diagnostic of Soft Tissue Sarcoma with metastasis limited to lung, and not suitable for metastasectomy or surgery resection or…
  • Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →